Abstract
PURPOSE
This study investigated the correlation between the prescription dose and dose to
the Manchester and International Commission on Radiation Units and Measurements-report
38 (ICRU-38) lymphatic trapezoid points during high-dose-rate (HDR) brachytherapy
of locally advanced cervical cancer with (Cobalt-60) 60Co .
METHODS AND MATERIALS
A retrospective study was designed for; patients with locally advanced cervical cancer,
treated by external beam radiotherapy and concurrent weekly Cisplatin-based chemotherapy,
had no extended parametrial invasion and was treated by tandem-ovoid set, from 2017
to 2020. Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology
(GEC-ESTRO) based target's volume, ICRU-89 revised version of Manchester points A
and B, and ICRU-38 lymph node surrogate points were determined, and their dose was
recorded. Paired sample t-test, linear regression analysis, and Pearson correlation analyses were done considering
a statistical significance level of 0.05 and using IBM SPSS statistics (Version 23,
IBM Crop.).
RESULTS
Seventy-four brachytherapy cases were included. A positive and strong correlation
was observed between D90 of clinical target volume (CTVHR) and points A and B dose for CTVHR〈 15 cc and 〉 35 cc. Strong and significant (p < 0.05) correlations were achieved between pelvic wall points dose and D90 and D100 of the obturator and between D50 and hot points of internal iliac lymph nodes. A strong correlation was obtained between
D50 and D90 of external iliac lymph nodes and their ICRU points.
CONCLUSIONS
Strong correlations were obtained between dose to the pelvic lymphatic chains and
their historical ICRU-38 surrogate points during HDR brachytherapy of locally advanced
cervical cancer patients with 60Co tandem-ovoid applicator sets. The correlation strength
between point A and prescription dose highly depends on the CTVHR volume.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The Impact of High-Dose-Rate Brachytherapy: Measuring Clinical Outcomes in the Primary Treatment of Cervical Cancer.Adv Radiat Oncol. 2020; 5: 419-425
- MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.Lancet Oncol. 2021; 22: 538-547
- Patterns of lymph node metastasis in locally advanced cervical cancer.Medicine (Baltimore). 2016; 95: e4814
- Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study.Int J Radiat Oncol Biol Phys. 2019 Jul 15; 104: 895-902
- Comparison of (60)Co and (192)Ir sources in HDR brachytherapy.J Contemp Brachytherapy. 2011; 3: 199-208
- Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.Med Phys. 2004; 31: 633-674
- Comparison of 60cobalt and 192iridium sources in high dose rate afterloading brachytherapy.Strahlenther Onkol. 2008; 184: 187-192
- A comparison of dose distributions of HDR intracavitary brachytherapy using different sources and treatment planning systems.Appl Radiat Isot. 2009; 67: 1426-1431
- Assessing dose contribution to pelvic lymph nodes in intracavitary brachytherapy for cervical cancer.J Contemp Brachytherapy. 2017; 9: 345-353
- Dose to pelvic lymph nodes in image based high dose rate brachytherapy of carcinoma cervix.Rep Pract Oncol Radiother. 2019; 24: 80-85
- Correlation of point B and lymph node dose in 3D-planned high-dose-rate cervical cancer brachytherapy.Int J Radiat Oncol Biol Phys. 2009; 75: 803-809
- Optimum organ volume ranges for organs at risk dose in cervical cancer intracavitary brachytherapy.J Contemp Brachytherapy. 2016; 8: 135-142
- Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.Radiother Oncol. 2005; 74: 235-245
- Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.Radiother Oncol. 2006; 78: 67-77
- Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy.Radiother Oncol. 2010; 96: 153-160
- Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability.Radiother Oncol. 2002; 63: 249-255
- Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas.Int J Radiat Oncol Biol Phys. 2012; 83: e353-e362
- A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer.Jpn J Clin Oncol. 2010; 40: 456-463
- Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy.Int J Radiat Oncol Biol Phys. 2005; 63: 1604-1612
- Prescribing, Recording and Reporting Brachytherapy for Cancer of the Cervix: International Commision of Radiation Unit and Measurement. 13. Oxford University Press, Oxford, UK2013: 133-141https://doi.org/10.1093/jicru/ndw042
- Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix.Int J Radiat Oncol Biol Phys. 2000; 48: 201-211
- Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology International Commission on Radiation Units and Mesurements.1985: 1-20https://doi.org/10.1093/jicru/os20.1.report38
- Alone and Combined with External-Beam Radiotherapy.J ICRU. 2013; 13: 105-122https://doi.org/10.1093/jicru/ndw009
- Dose to Pelvic Lymph Nodes with Image-Guided Brachytherapy in Patients with Locally Advanced Cervical Cancer.Brachytherapy. 2014; 13: S63-S64
- Dosimetric Contribution of Image Based Intracavitary Brachytherapy to Pelvic Lymphnodes in Locally Advanced Cervical Cancer.International Journal of Radiation Oncology, Biology, Physics. 2019; 105: E321-EE22
- Straightforward Statistics for the Behavioral Sciences.Cole Publishing Company, 1996
- A comparison between revised Manchester Point A and ICRU-89-recommended Point A definition absorbed-dose reporting using CT images in intracavitary brachytherapy for patients with cervical carcinoma.Brachytherapy. 2021; 20: 118-127
- Evaluation of linear array MOSFET detectors for in vivo dosimetry to measure rectal dose in HDR brachytherapy.Australas Phys Eng Sci Med. 2011; 34: 361-366
- Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study.Radiother Oncol. 2016; 120: 434-440
- Point A vs. HR-CTV D90 in MRI-based cervical brachytherapy of small and large lesions.Brachytherapy. 2016; 15: 825-831
- Prescribing, Recording and Reporting Brachytherapy for Cancer of the Cervix: International Commision of Radiation Unit and Measurement. 13. Oxford University Press, Oxford, UK2013: 133-141https://doi.org/10.1093/jicru/ndw042
- Study of positional dependence of dose to bladder, pelvic wall and rectal points in High-Dose-Rate Brachytherapy in cervical cancer patients.J Med Phys. 2013; 38: 178-184
- Application of the ICRU Report 38 reference volume concept to the radiotherapeutic management of recurrent endometrial and cervical carcinoma.Radiother Oncol. 1993; 26: 254-259
- Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer.J Contemp Brachytherapy. 2019; 11: 137-145
- Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.J Surg Oncol. 2019; 119: 856-863
- Dose-effect response in image-guided adaptive brachytherapy for cervical cancer: A systematic review and meta-regression analysis.Brachytherapy. 2020; 19: 438-446
- Carcinoma of the uterine cervix: a 3D - CT analysis of dose to the internal, external and common iliac nodes in tandem and ovoid applications.Radiother Oncol. 2000; 56: 43-48
- Delineating the relationship between Point A prescription dose and pelvic lymph node doses in intracavitary high-dose-rate brachytherapy treatment of cervical cancer for use in low- and middle-income countries.Brachytherapy. 2018; 17: 201-207
Article info
Publication history
Published online: November 06, 2021
Accepted:
September 29,
2021
Received in revised form:
September 27,
2021
Received:
July 4,
2021
Footnotes
Disclosure: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Zahra Siavashpour: There is nothing to disclose. There is no conflict of interest. Mona Malekzadeh Moghani: There is nothing to disclose. There is no conflict of interest. Ramin Jaberi: There is nothing to disclose. There is no conflict of interest. Farid Zayeri: There is nothing to disclose. There is no conflict of interest. Shabnam Anjidani: There is nothing to disclose. There is no conflict of interest. Maedeh Maleki: There is nothing to disclose. There is no conflict of interest. Mahdi Aghili: There is nothing to disclose. There is no conflict of interest.
Identification
Copyright
© 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
